Author

Maria O'Donovan

CYTOSPONGE-TFF3 TESTING CAN DETECT PRE-CANCEROUS MUCOSAL CHANGES OF THE STOMACH
CYTOSPONGE-TFF3 TESTING CAN DETECT PRE-CANCEROUS MUCOSAL CHANGES OF THE STOMACH

Maria O'Donovan  et al.

SIMPLE CYTOSPONGE-BIOMARKER TECHNOLOGY TO PRIORITIZE ENDOSCOPIC BARRETT’S ESOPHAGUS SURVEILLANCE
SIMPLE CYTOSPONGE-BIOMARKER TECHNOLOGY TO PRIORITIZE ENDOSCOPIC BARRETT’S ESOPHAGUS SURVEILLANCE

Maria O'Donovan  et al.

CYTOSPONGE AS A TRIAGING TOOL TO UPPER GI ENDOSCOPY DURING COVID-19 PANDEMIC
CYTOSPONGE AS A TRIAGING TOOL TO UPPER GI ENDOSCOPY DURING COVID-19 PANDEMIC

Maria O'Donovan  et al.

STRUCTURAL VARIANT EVENTS DOMINATE A MOLECULAR CONTINUUM IN THE PROGRESSION OF BARRETT'S OESOPHAGUS
STRUCTURAL VARIANT EVENTS DOMINATE A MOLECULAR CONTINUUM IN THE PROGRESSION OF BARRETT'S OESOPHAGUS

Maria O'Donovan  et al.

MODELLING FROM A MULTICENTRE, PRAGMATIC, RANDOMISED CONTROLLED TRIAL IDENTIFIES THE TARGET SCREENING POPULATION AND EXPECTED YIELD FOR BARRETT’S ESOPHAGUS AND ESOPHAGEAL CANCER DIAGNOSES
MODELLING FROM A MULTICENTRE, PRAGMATIC, RANDOMISED CONTROLLED TRIAL IDENTIFIES THE TARGET SCREENING POPULATION AND EXPECTED YIELD FOR BARRETT’S ESOPHAGUS AND ESOPHAGEAL CANCER DIAGNOSES

Maria O'Donovan  et al.

FEASIBILITY OF THE CYTOSPONGE COUPLED WITH TISSUE BIOMARKERS IN EARLY DIAGNOSIS OF OESOPHAGEAL SQUAMOUS CELL CARCINOMA AND SURVEILLANCE OF HIGH-RISK INDIVIDUALS: PRELIMINARY RESULTS FROM THE EDEN STUDY
FEASIBILITY OF THE CYTOSPONGE COUPLED WITH TISSUE BIOMARKERS IN EARLY DIAGNOSIS OF OESOPHAGEAL SQUAMOUS CELL CARCINOMA AND SURVEILLANCE OF HIGH-RISK INDIVIDUALS: PRELIMINARY RESULTS FROM THE EDEN STUDY

Maria O'Donovan  et al.

OPTIMAL PROCEDURAL TIME ENSURES ADHERENCE TO SEATTLE PROTOCOL AND MAXIMIZES DYSPLASIA DETECTION IN BARRETT’S ESOPHAGUS SURVEILLANCE
OPTIMAL PROCEDURAL TIME ENSURES ADHERENCE TO SEATTLE PROTOCOL AND MAXIMIZES DYSPLASIA DETECTION IN BARRETT’S ESOPHAGUS SURVEILLANCE

Maria O'Donovan  et al.

RANGE OF PATHOLOGIES DIAGNOSED AMONG A SCREENING POPULATION OF PATIENTS WITH REFLUX DISEASE: RESULTS FROM THE CYTOSPONGE-BEST3 TRIAL
RANGE OF PATHOLOGIES DIAGNOSED AMONG A SCREENING POPULATION OF PATIENTS WITH REFLUX DISEASE: RESULTS FROM THE CYTOSPONGE-BEST3 TRIAL

Maria O'Donovan  et al.

THE UTILITY OF A MULTI-GENE METHYLATION PANEL TO RISK-STRATIFY PATIENTS WITH BARRETT’S ESOPHAGUS AFTER RADIOFREQUENCY ABLATION
THE UTILITY OF A MULTI-GENE METHYLATION PANEL TO RISK-STRATIFY PATIENTS WITH BARRETT’S ESOPHAGUS AFTER RADIOFREQUENCY ABLATION

Maria O'Donovan  et al.

Item 1 - 9 / 9
1